https://orcid.org/0000-0002-0518-0456
Abstract
Introduction
The episodic or on-demand administration of clotting factor concentrates in hemophilia patients in the event of hemorrhage is employed to restore hemostasis. Adherence to on-demand treatments needs to be assessed in order to improve patient management, avoiding adverse effects and serious clinical complications.
Aim
To validate the Spanish version of the treatment adherence scale in patients with hemophilia, namely, Validated Hemophilia Regimen Treatment Adherence Scale-PRN (VERITAS-PRN).
Methods
Eighty-five patients were recruited in three hemophilia patient associations in Spain. The VERITAS-PRN scale was adapted through a back-translation process from English to Spanish. A native Spanish bilingual translator translated the scale from English to Spanish, and subsequently another native English bilingual translator translated the scale from Spanish to English. The scale was applied twice (two months apart) to assess test–retest reliability.
Results
Internal consistency reliability was slightly lower in the VERITAS-PRN in Spanish (0.80) versus the English version (0.85). There were no differences (p > 0.05) between the means of the dimensions or in the total scores between the sample of patients in Spain and the USA. The test–retest reliability coefficient of the scores on the total scale was 0.80 [CI, 0.74–0.86]. The test–retest reliability coefficient was greater than 0.90 in all subscales.
Conclusion
The Spanish version of VERITAS-PRN has high consistency and empirical validity. This scale is useful for assessing the degree of adherence to treatment in adult patients with hemophilia following episodic infusion treatment.
Data Sharing Statement
The dataset used is available from the corresponding author upon request. Encoded data without personal identification shall solely be provided to those directly requesting same for scientific purposes.
Ethics and Consent to Participate
The study was approved by the Ethics Committee of the Universidad Católica San Antonio of Murcia (id.24/7/15) and the Spanish Agency for Medicines and Health Products (id.16190/RG32244).
Acknowledgments
The authors are especially grateful to Regional Murciana Association of Hemophilia, Association of Hemophilia of Burgos, Gallega Association of Hemophilia and the Spanish Federation of Hemophilia, for their help in recruitment of the sample.
Disclosure
The authors certify that there are no conflicts of interest with any financial organization regarding the material discussed in the manuscript.